KR20030040538A - 5-ht3 수용체 길항제를 사용한 메트포르민의 구토작용의 억제 - Google Patents
5-ht3 수용체 길항제를 사용한 메트포르민의 구토작용의 억제 Download PDFInfo
- Publication number
- KR20030040538A KR20030040538A KR10-2003-7005263A KR20037005263A KR20030040538A KR 20030040538 A KR20030040538 A KR 20030040538A KR 20037005263 A KR20037005263 A KR 20037005263A KR 20030040538 A KR20030040538 A KR 20030040538A
- Authority
- KR
- South Korea
- Prior art keywords
- metformin
- alkyl
- group
- receptor antagonist
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Description
Claims (10)
- (i) 약제학적 유효량의 메트포르민;(ii) 상기 메트포르민에 의해 야기되는 구토증을 억제하는데에 유효한 양의 5-히드록시트립타민-3 수용체 길항제; 및(iii) 약제학적으로 허용되는 담체를 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 5-히드록시트립타민-3 수용체 길항제는 화학식을 갖는 치환된 1H-인돌 5-히드록시트립타민이며,상기식에서 R1은 H 및 저급 알킬로 구성된 군으로부터 선택되는 구성원이고;R2및 R3는 결합하여 다음으로 구성된 군으로부터 선택되는 화학식을 갖는 2가 구조를 형성하는데, 상기 식에서 *는 부착 부위를 표시하고, R4는 N 및 CH로 구성된 군으로부터 선택되는 구성원이고, R5, R6, 및 R7은 독립적으로 수소, 저급 알킬, 시클로알킬, 및 저급 알케닐로 구성된 군으로부터 선택되는 구성원이거나; 아니면R2는 N 및 CH로 구성된 군으로부터 선택되는 구성원이고, R3은 화학식의 구조인데, 상기 식에서 *는 부착 부위를 표시하고, R8은 NH 및 O로 구성된 군으로부터 선택되는 구성원이고, R9는 N 및 CH로 구성된 군으로부터 선택되는 구성원이고,R10이 저급 2가 알킬이고 R11이 H 및 저급 알킬로 구성된 군으로부터 선택되는 구성원이거나, 아니면R10및 R11이 결합하여 저급 3가 알킬 및 옥소-치환된 저급 3가 알킬로 구성된 군으로부터 선택되는 3가 구조를 형성하는 것을 특징으로 하는 약제학적 조성물.
- 제 2 항에 있어서, R5, R6, 및 R7은 독립적으로 H 및 C1-C3알킬로 구성된 군으로부터 선택되는 구성원이고, R9는 N이고,R10이 2가 C2-C3알킬이고 R11이 H이거나, 아니면R10및 R11이 결합하여 C4-C63가 알킬 및 옥소-치환된 C4-C63가 알킬로 구성된 군으로부터 선택되는 구조를 형성하는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 5-히드록시트립타민-3 수용체 길항제는 온단세트론인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 5-히드록시트립타민-3 수용체 길항제는 돌라세트론인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 5-히드록시트립타민-3 수용체 길항제는 그라니세트론인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 5-히드록시트립타민-3 수용체 길항제는 트로피세트론인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 메트포르민 및 상기 5-히드록시트립타민-3 수용체길항제는 약 1:0.0003 내지 약 0.5:1의 중량비로 존재하는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 메트포르민은 지속-방출 상태로 상기 조성물에 보유되고 상기 5-히드록시트립타민-3 수용체 길항제는 즉각-방출 상태로 상기 조성물에 보유되는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 상기 메트포르민은 지속-방출 정제로 상기 조성물에 보유되고 상기 5-히드록시트립타민-3 수용체 길항제는 상기 정제의 표면 상의 신속-방출 층에 보유되는 것을 특징으로 하는 약제학적 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/691,398 US6451808B1 (en) | 2000-10-17 | 2000-10-17 | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
US09/691,398 | 2000-10-17 | ||
PCT/US2001/042751 WO2002032416A2 (en) | 2000-10-17 | 2001-10-16 | Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030040538A true KR20030040538A (ko) | 2003-05-22 |
KR100907640B1 KR100907640B1 (ko) | 2009-07-14 |
Family
ID=24776400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037005263A KR100907640B1 (ko) | 2000-10-17 | 2001-10-16 | 5-ht3 수용체 길항제를 사용한 메트포르민의 구토작용의 억제 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6451808B1 (ko) |
EP (1) | EP1326643B1 (ko) |
JP (1) | JP2004522700A (ko) |
KR (1) | KR100907640B1 (ko) |
AT (1) | ATE314090T1 (ko) |
AU (2) | AU2002211923B2 (ko) |
CA (1) | CA2422711C (ko) |
DE (1) | DE60116353T2 (ko) |
ES (1) | ES2251516T3 (ko) |
IL (1) | IL154988A0 (ko) |
MX (1) | MXPA03003128A (ko) |
NZ (1) | NZ524790A (ko) |
PT (1) | PT1326643E (ko) |
WO (1) | WO2002032416A2 (ko) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
WO2003035039A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
DE60329187D1 (de) * | 2002-07-20 | 2009-10-22 | Acea Biosciences Inc | Impedanz basierende vorrichtungen und verfahren zur analyse von zellen und partikeln |
KR20050111318A (ko) | 2003-01-13 | 2005-11-24 | 다이노젠 파마세우티컬스, 인코포레이티드 | 기능성 장 질환을 치료하는 방법 |
EP1680083A1 (en) * | 2003-10-31 | 2006-07-19 | ALZA Corporation | Compositions and dosage forms for ehnanced absorption of iron |
ES2314749T3 (es) * | 2004-12-21 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados de tetralina y de indano y usos de los mismos como antagonistas de 5-ht. |
AU2006329564A1 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
WO2010129686A1 (en) | 2009-05-05 | 2010-11-11 | Vapogenix, Inc. | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
EP2603215A4 (en) | 2010-08-11 | 2015-08-05 | Philadelphia Health & Educatio | NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE |
US8944342B2 (en) | 2010-11-02 | 2015-02-03 | M&R Consulting Services, Inc. | Two-part, wall-mountable electrochemical dispenser |
EP2648754A4 (en) | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHODS OF INHIBITING THE METASTASIS OF CANCER |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
KR20140035331A (ko) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
TWI519515B (zh) | 2011-12-21 | 2016-02-01 | 諾維拉治療公司 | B型肝炎抗病毒劑 |
KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
JP6175074B2 (ja) | 2012-01-06 | 2017-08-02 | エルセリクス セラピューティクス インコーポレイテッド | 代謝障害を治療するための組成物および方法 |
CA2879454A1 (en) | 2012-07-19 | 2014-01-23 | Drexel University | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
EP2950790A4 (en) | 2012-08-09 | 2018-04-25 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
MX2015008773A (es) | 2013-01-07 | 2015-11-06 | Univ Pennsylvania | Composiciones y metodos para tratar linfoma cutaneo de celulas t. |
WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
RU2673737C2 (ru) | 2013-07-02 | 2018-11-29 | ЭКОПЛЭНЕТ ЭНВАЙРОНМЕНТАЛ, ЭлЭлСи | Композиции летучих органических веществ, обладающие антимикробной активностью |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
EP3074049B1 (en) | 2013-11-26 | 2020-05-06 | Yale University | Novel cell-penetrating compositions and methods using same |
US10258615B2 (en) | 2013-12-09 | 2019-04-16 | Thomas Jefferson University | Methods of treating a neurodegenerative disease in a mammal in need thereof |
US9982010B2 (en) | 2014-04-07 | 2018-05-29 | Women & Infants Hospital Of Rhode Island | 7-dehydrocholesterol derivatives and methods using same |
US10624917B2 (en) | 2014-08-20 | 2020-04-21 | Yale University | Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss |
US9695517B2 (en) | 2014-12-29 | 2017-07-04 | M & R Consulting Services, Inc. | Two-part, wall-mountable electrochemical dispenser |
CA2978593A1 (en) * | 2015-01-12 | 2016-07-21 | Nano Pharmaceutical Laboratories Llc | Layered sustained-release microbeads and methods of making the same |
WO2016182968A1 (en) | 2015-05-08 | 2016-11-17 | Brown University | Novel syringolin analogues and methods of making and using same |
JP6995627B2 (ja) | 2015-05-19 | 2022-02-04 | イエール ユニバーシティ | 病的石灰化状態を治療するための組成物およびそれを使用する方法 |
WO2016201288A1 (en) | 2015-06-12 | 2016-12-15 | Brown University | Novel antibacterial compounds and methods of making and using same |
NO346258B1 (en) | 2015-06-30 | 2022-05-16 | Neurad Ltd | Novel breathing control modulating compounds, and methods of making and using same |
WO2017075145A1 (en) | 2015-10-28 | 2017-05-04 | Yale University | Quinoline amides and methods of using same |
CA3005142A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
WO2017190001A1 (en) | 2016-04-29 | 2017-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and compositions useful for treating metabolic syndrome, and methods using same |
US20210330599A1 (en) | 2016-08-01 | 2021-10-28 | University Of Rochester | Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use |
US11390859B2 (en) | 2016-08-05 | 2022-07-19 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
WO2018045229A1 (en) | 2016-09-01 | 2018-03-08 | Mebias Discovery Llc | Substituted ureas and methods of making and using same |
CN110114071B (zh) | 2016-11-07 | 2023-07-04 | 爱彼特生物制药公司 | 含有取代的吡啶酮的三环化合物以及使用其的方法 |
WO2018136766A1 (en) | 2017-01-19 | 2018-07-26 | Temple University-Of The Commonwealth System Of Higher Education | Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
JP7108018B2 (ja) | 2017-04-17 | 2022-07-27 | イエール ユニバーシティ | 急性肺傷害を処置または予防する化合物、組成物および方法 |
US20210085796A1 (en) | 2017-07-28 | 2021-03-25 | Yale University | Anticancer drugs and methods of making and using same |
US11426409B2 (en) | 2017-09-08 | 2022-08-30 | The Regents Of The University Of Colorado | Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers |
CN111818929A (zh) | 2017-11-27 | 2020-10-23 | 由卫生与公众服务部部长代表的美利坚合众国 | 用于治疗和/或预防牙周疾病的化合物、组合物和方法 |
WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
CA3089236A1 (en) | 2018-01-24 | 2019-08-01 | The Rockefeller University | Antibacterial compounds, compositions thereof, and methods using same |
US11091473B2 (en) | 2018-05-29 | 2021-08-17 | Acadia Pharmaceuticals Inc. | Compounds for pain treatment, compositions comprising same, and methods of using same |
KR20240042554A (ko) | 2018-10-11 | 2024-04-02 | 사니핏 테라퓨틱스 에스.에이. | 이소성 석회화의 치료를 위한 이노시톨 포스페이트 |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
BR112021014897A2 (pt) | 2019-01-30 | 2021-09-28 | Sanifit Therapeutics, S.A. | Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
US20200246317A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent |
WO2020159565A1 (en) | 2019-02-01 | 2020-08-06 | Cersci Therapeutics, Inc. | Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent |
WO2020227603A1 (en) | 2019-05-09 | 2020-11-12 | The Feinstein Institutes For Medical Research | Hmgb1 antagonist |
US11555010B2 (en) | 2019-07-25 | 2023-01-17 | Brown University | Diamide antimicrobial agents |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
CA3181983A1 (en) | 2020-06-09 | 2021-12-16 | Zhiliang Cheng | Soluble enpp1 or enpp3 proteins and uses thereof |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
WO2023278300A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024052895A1 (en) | 2022-09-06 | 2024-03-14 | Hadasit Medical Research Services And Development Ltd | Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
CA2067754C (en) * | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
US5576306A (en) | 1991-03-01 | 1996-11-19 | Dow Chemical Company | Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
EP1039890B1 (en) | 1997-12-08 | 2004-03-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
-
2000
- 2000-10-17 US US09/691,398 patent/US6451808B1/en not_active Expired - Lifetime
-
2001
- 2001-10-16 EP EP01980020A patent/EP1326643B1/en not_active Expired - Lifetime
- 2001-10-16 IL IL15498801A patent/IL154988A0/xx unknown
- 2001-10-16 AT AT01980020T patent/ATE314090T1/de not_active IP Right Cessation
- 2001-10-16 JP JP2002535654A patent/JP2004522700A/ja active Pending
- 2001-10-16 MX MXPA03003128A patent/MXPA03003128A/es active IP Right Grant
- 2001-10-16 KR KR1020037005263A patent/KR100907640B1/ko active IP Right Grant
- 2001-10-16 CA CA002422711A patent/CA2422711C/en not_active Expired - Fee Related
- 2001-10-16 AU AU2002211923A patent/AU2002211923B2/en not_active Ceased
- 2001-10-16 DE DE60116353T patent/DE60116353T2/de not_active Expired - Lifetime
- 2001-10-16 PT PT01980020T patent/PT1326643E/pt unknown
- 2001-10-16 AU AU1192302A patent/AU1192302A/xx active Pending
- 2001-10-16 NZ NZ524790A patent/NZ524790A/en not_active IP Right Cessation
- 2001-10-16 ES ES01980020T patent/ES2251516T3/es not_active Expired - Lifetime
- 2001-10-16 WO PCT/US2001/042751 patent/WO2002032416A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
DE60116353D1 (de) | 2006-02-02 |
ATE314090T1 (de) | 2006-01-15 |
KR100907640B1 (ko) | 2009-07-14 |
AU1192302A (en) | 2002-04-29 |
EP1326643A2 (en) | 2003-07-16 |
CA2422711C (en) | 2009-07-07 |
US6451808B1 (en) | 2002-09-17 |
AU2002211923B2 (en) | 2005-12-01 |
PT1326643E (pt) | 2006-05-31 |
EP1326643B1 (en) | 2005-12-28 |
JP2004522700A (ja) | 2004-07-29 |
ES2251516T3 (es) | 2006-05-01 |
IL154988A0 (en) | 2003-10-31 |
MXPA03003128A (es) | 2003-07-14 |
WO2002032416A2 (en) | 2002-04-25 |
WO2002032416A3 (en) | 2003-03-27 |
DE60116353T2 (de) | 2006-08-24 |
CA2422711A1 (en) | 2002-04-25 |
NZ524790A (en) | 2005-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100907640B1 (ko) | 5-ht3 수용체 길항제를 사용한 메트포르민의 구토작용의 억제 | |
AU2002211923A1 (en) | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists | |
US6251430B1 (en) | Water insoluble polymer based sustained release formulation | |
EP0250023B1 (en) | Nitrofurantoin dosage form | |
US20040131671A1 (en) | Sustained release formulations containing acetaminophen and tramadol | |
AU2006233567A1 (en) | Therapeutic combination in case of benign prostate hyperplasia | |
CN1116926A (zh) | 控制活性成分在肠道靶部位释放的药物制剂 | |
KR20060115860A (ko) | 활성 제제의 서방성 전달을 위한 oros 푸시-스틱 | |
US20070160671A1 (en) | Biguanide formulations | |
US8206742B2 (en) | Sustained release compositions of alfuzosin | |
US20060002997A1 (en) | Nitrofurantoin controlled release dosage form | |
MXPA05004338A (es) | Composiciones de liberacion sostenida que contienen alfuzosin. | |
EP2010158B1 (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
WO2003030920A9 (en) | An antispasmodic agent spaced drug delivery system | |
WO2008114276A1 (en) | Novel oral controlled release composition of carvedilol | |
KR960000429B1 (ko) | 니트로푸란토인의 경구투여용 서방성/속방성 약제학적 복합 캅셀 | |
US20050032876A1 (en) | Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof | |
CA2463168A1 (en) | An antispasmodic agent spaced drug delivery system | |
US8846084B2 (en) | Controlled release compositions containing zolpidem | |
US20010036474A1 (en) | Endo-N-(9- methyl-9-azabicyclo[3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride | |
US20010005722A1 (en) | endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride | |
US20090162431A1 (en) | Sustained release formulations containing acetaminophen and tramadol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130625 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140625 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150624 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160627 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180627 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190626 Year of fee payment: 11 |